Multiple Sclerosis Research Repository

1. Ublituximab-xiiy (Briumvi) National Drug Monograph, June 2023, VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives:

1. Percent of brain volume change and all disabilty-related secondary outcomes were not significant 
2. Ublituximab did not have a statistically significant difference in confirmed disability progression compared to teriflunomide 

2) Briumvi FDA Prescribing Information (20 page document)

1. There was no statistically significant difference in disability progression confirmed at 12 weeks between Briumvi-treated and teriflunomide-treated patients